David J Fabrizio, 63Waukesha, WI
David Fabrizio Phones & Addresses
Waukesha, WI
Quincy, MA
Braintree, MA
3801 Chanticleer Ct, Tallahassee, FL 32311 850-3091941
Baton Rouge, LA
Denham Springs, LA
Elk Grove, CA
Manteca, CA
Modesto, CA
East Taunton, MA
Mentions for David J Fabrizio
Publications & IP owners
Us Patents
Targeted Therapeutics Based On Engineered Proteins That Bind Egfr
US Patent:
8524244, Sep 3, 2013
Filed:
Feb 10, 2009
Appl. No.:
12/867406
Inventors:
Ray Camphausen - Wayland MA, US
Brent Morse - Newton Center MA, US
Stuart Emanuel - Doylestown PA, US
David Fabrizio - Swampscott MA, US
Brent Morse - Newton Center MA, US
Stuart Emanuel - Doylestown PA, US
David Fabrizio - Swampscott MA, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 38/17
A61K 38/39
A61K 47/48
C07K 14/71
C07K 14/435
A61K 38/39
A61K 47/48
C07K 14/71
C07K 14/435
US Classification:
4241851, 4241931, 42419511, 514 93, 514 192, 530350, 530402
Abstract:
The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
Targeted Therapeutics Based On Engineered Proteins For Tyrosine Kinases Receptors, Including Igf-Ir
US Patent:
2010012, May 13, 2010
Filed:
Nov 21, 2007
Appl. No.:
12/312725
Inventors:
Ray Camphausen - Wayland MA, US
David Fabrizio - Swampscott MA, US
Martin C. Wright - Boston MA, US
Patrick Gage - Bala Cynwyd PA, US
John Mendlein - Scituate MA, US
David Fabrizio - Swampscott MA, US
Martin C. Wright - Boston MA, US
Patrick Gage - Bala Cynwyd PA, US
John Mendlein - Scituate MA, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
C07K 14/765
C07K 14/00
C07K 16/00
C07K 14/79
C07K 14/00
C07K 16/00
C07K 14/79
US Classification:
530363, 530350, 5303873, 5303911, 530394
Abstract:
The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.
Serum Albumin Binding Molecules
US Patent:
2011030, Dec 15, 2011
Filed:
May 2, 2011
Appl. No.:
13/098851
Inventors:
Michael L. Gosselin - Boston MA, US
David Fabrizio - Swampscott MA, US
Joanna F. Swain - Concord MA, US
Tracy Mitchell - Billerica MA, US
Ray Camphausen - Wayland MA, US
Sharon T. Cload - Cambridge MA, US
Eric Furfine - Concord MA, US
Paul E. Morin - Pennington NJ, US
Ranjan Mukherjee - Churchville PA, US
Simeon I. Taylor - Skillman NJ, US
David Fabrizio - Swampscott MA, US
Joanna F. Swain - Concord MA, US
Tracy Mitchell - Billerica MA, US
Ray Camphausen - Wayland MA, US
Sharon T. Cload - Cambridge MA, US
Eric Furfine - Concord MA, US
Paul E. Morin - Pennington NJ, US
Ranjan Mukherjee - Churchville PA, US
Simeon I. Taylor - Skillman NJ, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 38/20
C07K 19/00
A61K 38/17
A61P 3/10
A61P 3/04
A61K 38/18
A61K 38/28
A61K 38/22
A61K 38/26
C07H 21/00
C12N 15/63
C12N 5/10
C12N 1/21
A61P 3/00
A61P 3/06
A61P 9/00
C07K 14/47
C07K 19/00
A61K 38/17
A61P 3/10
A61P 3/04
A61K 38/18
A61K 38/28
A61K 38/22
A61K 38/26
C07H 21/00
C12N 15/63
C12N 5/10
C12N 1/21
A61P 3/00
A61P 3/06
A61P 9/00
C07K 14/47
US Classification:
424 852, 530324, 530350, 530399, 530351, 514 11, 514 69, 514 48, 514 91, 514 59, 514 88, 514 52, 514 72, 514 117, 514 97, 536 235, 4353201, 435325, 4352523
Abstract:
The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
Targeted Therapeutics Based On Engineered Proteins For Tyrosine Kinases Receptors, Including Igf-Ir
US Patent:
2013031, Nov 21, 2013
Filed:
May 13, 2013
Appl. No.:
13/892418
Inventors:
Bristol-Myers Squibb Company - , US
David FABRIZIO - South Hamilton MA, US
Martin C. WRIGHT - Belmont MA, US
Patrick GAGE - Bryn Mawr PA, US
John MENDLEIN - Encinitas CA, US
David FABRIZIO - South Hamilton MA, US
Martin C. WRIGHT - Belmont MA, US
Patrick GAGE - Bryn Mawr PA, US
John MENDLEIN - Encinitas CA, US
Assignee:
BRISTOL-MYERS SQUIBB COMPANY - Princeton NJ
International Classification:
A61K 38/18
C07K 16/00
C07K 14/79
C07K 14/00
C07K 14/765
C07K 16/00
C07K 14/79
C07K 14/00
C07K 14/765
US Classification:
514 87, 530324, 530363, 530394, 5303873, 514 213, 536 231, 4353201
Abstract:
The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.
Targeted Therapeutics Based On Engineered Proteins That Bind Egfr
US Patent:
2014003, Feb 6, 2014
Filed:
Aug 1, 2013
Appl. No.:
13/956952
Inventors:
Brent MORSE - Newton MA, US
Stuart EMANUEL - Doylestown PA, US
David FABRIZIO - South Hamilton MA, US
Stuart EMANUEL - Doylestown PA, US
David FABRIZIO - South Hamilton MA, US
Assignee:
BRISTOL-MYERS SQUIBB COMPANY - Princeton NJ
International Classification:
C07K 14/78
C07K 19/00
C07K 14/79
C07K 14/765
C07K 19/00
C07K 14/79
C07K 14/765
US Classification:
514 93, 530324, 536 235, 530350, 530363, 5303873, 530394
Abstract:
The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
Serum Albumin-Binding Fibronectin Type Iii Domains
US Patent:
2022020, Jun 30, 2022
Filed:
Nov 16, 2021
Appl. No.:
17/527238
Inventors:
- Princeton NJ, US
Michael L. Gosselin - Boston MA, US
Dasa Lipovsek - Pepperell MA, US
Rex Parker - Titusville NJ, US
Ray Camphausen - Wayland MA, US
Jonathan H. Davis - Madison WI, US
David Fabrizio - South Hamilton MA, US
Michael L. Gosselin - Boston MA, US
Dasa Lipovsek - Pepperell MA, US
Rex Parker - Titusville NJ, US
Ray Camphausen - Wayland MA, US
Jonathan H. Davis - Madison WI, US
David Fabrizio - South Hamilton MA, US
International Classification:
C07K 14/78
A61K 47/64
A61K 47/64
Abstract:
The present invention relates to polypeptides which include tenth fibronectin type III domains (Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
Targeted Therapeutics Based On Engineered Proteins That Bind Egfr
US Patent:
2021004, Feb 11, 2021
Filed:
Aug 19, 2020
Appl. No.:
16/997282
Inventors:
- Princeton NJ, US
Brent MORSE - Newton MA, US
Stuart EMANUEL - Doylestown PA, US
David FABRIZIO - South Hamilton MA, US
Brent MORSE - Newton MA, US
Stuart EMANUEL - Doylestown PA, US
David FABRIZIO - South Hamilton MA, US
International Classification:
C07K 14/78
C07K 16/28
C07K 14/765
C07K 14/79
C07K 19/00
C07K 16/28
C07K 14/765
C07K 14/79
C07K 19/00
Abstract:
The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
Serum Albumin-Binding Fibronectin Type Iii Domains
US Patent:
2020004, Feb 13, 2020
Filed:
Aug 23, 2019
Appl. No.:
16/549462
Inventors:
- PRINCETON NJ, US
Michael L. GOSSELIN - Boston MA, US
Dasa LIPOVSEK - Cambridge MA, US
Rex PARKER - Titusville NJ, US
Ray CAMPHAUSEN - Wayland MA, US
Jonathan DAVIS - Auburndale MA, US
David FABRIZIO - South Hamilton MA, US
Michael L. GOSSELIN - Boston MA, US
Dasa LIPOVSEK - Cambridge MA, US
Rex PARKER - Titusville NJ, US
Ray CAMPHAUSEN - Wayland MA, US
Jonathan DAVIS - Auburndale MA, US
David FABRIZIO - South Hamilton MA, US
International Classification:
C07K 14/78
A61K 47/64
A61K 47/64
Abstract:
The present invention relates to polypeptides which include tenth fibronectin type III domains (Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.